BIOMAT Database Logo BIOMAT Database Logo

Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes. 2000

A A Link, and T Kino, and J A Worth, and J L McGuire, and M L Crane, and G P Chrousos, and R L Wilder, and I J Elenkov
Developmental Endocrinology Branch, National Institute of Child Health and Human Development, Bethesda, MD 20892, USA.

Adenosine (ADO) exerts potent anti-inflammatory and immunosuppressive effects. In this paper we address the possibility that these effects are partly mediated by inhibition of the secretion of IL-12, a proinflammatory cytokine and a major inducer of Th1 responses. We demonstrate that 5'-N-ethylcarboxamidoadenosine (NECA), a nonspecific ADO analogue, and 2-p-(2-carbonyl-ethyl)phenylethylamino-5'-N-ethylcarboxamidoadenos ine (CGS-21680), a specific A2a receptor agonist, dose-dependently inhibited, in whole blood ex vivo and monocyte cultures, the production of human IL-12 induced by LPS and Stapholococcus aureus Cowan strain 1. However, the A1 receptor agonist 2-Chloro-N6-cyclopentyladenosine and the A3 receptor agonists N6-Benzyl-NECA and 1-deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-N-methyl-be ta-d -ribofuranuronamide expressed only weak inhibitory effects. On the other hand, NECA and CGS-21680 dose-dependently potentiated the production of IL-10. The differential effect of these drugs on monocyte IL-12 and IL-10 production implies that these effects are mediated by A2a receptor signaling rather than by intracellular toxicity of ADO analogue's metabolites. Moreover, CGS-21680 inhibited IL-12 production independently of endogenous IL-10 induction, because anti-IL-10 Abs failed to prevent its effect. The selective A2a antagonist 8-(3-Chlorostyryl) caffeine prevented the inhibitory effect of CGS-21680 on IL-12 production. The phosphodiesterase inhibitor Ro 20-1724 dose-dependently potentiated the inhibitory effect of CGS-21680 and, furthermore, Rp-cAMPS, a protein kinase A inhibitor, reversed the inhibitory effect of CGS-21680, implicating a cAMP/protein kinase A pathway in its action. Thus, ligand activation of A2a receptors simultaneously inhibits IL-12 and stimulates IL-10 production by human monocytes. Through this mechanism, ADO released in excess during inflammatory and ischemic conditions, or tissue injury, may contribute to selective suppression of Th1 responses and cellular immunity.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008297 Male Males
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D010627 Phenethylamines A group of compounds that are derivatives of beta- aminoethylbenzene which is structurally and pharmacologically related to amphetamine. (From Merck Index, 11th ed) Phenylethylamines
D002110 Caffeine A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine's most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes SMOOTH MUSCLE, stimulates CARDIAC MUSCLE, stimulates DIURESIS, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide PHOSPHODIESTERASES, antagonism of ADENOSINE RECEPTORS, and modulation of intracellular calcium handling. 1,3,7-Trimethylxanthine,Caffedrine,Coffeinum N,Coffeinum Purrum,Dexitac,Durvitan,No Doz,Percoffedrinol N,Percutaféine,Quick-Pep,Vivarin,Quick Pep,QuickPep
D004306 Dose-Response Relationship, Immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. Immunologic Dose-Response Relationship,Relationship, Immunologic Dose-Response,Dose Response Relationship, Immunologic,Dose-Response Relationships, Immunologic,Immunologic Dose Response Relationship,Immunologic Dose-Response Relationships,Relationship, Immunologic Dose Response,Relationships, Immunologic Dose-Response
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A A Link, and T Kino, and J A Worth, and J L McGuire, and M L Crane, and G P Chrousos, and R L Wilder, and I J Elenkov
Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms.
October 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
A A Link, and T Kino, and J A Worth, and J L McGuire, and M L Crane, and G P Chrousos, and R L Wilder, and I J Elenkov
Activation of adenosine A2A receptors inhibits neutrophil transuroepithelial migration.
August 2011, Infection and immunity,
A A Link, and T Kino, and J A Worth, and J L McGuire, and M L Crane, and G P Chrousos, and R L Wilder, and I J Elenkov
The role of adenosine A2A and A2B receptors in the regulation of TNF-alpha production by human monocytes.
March 2005, Biochemical pharmacology,
A A Link, and T Kino, and J A Worth, and J L McGuire, and M L Crane, and G P Chrousos, and R L Wilder, and I J Elenkov
Adenosine A2A-receptor stimulation inhibits lipopolysaccharide-induced interleukin-18 production in monocytes.
June 2007, Journal of pharmacological sciences,
A A Link, and T Kino, and J A Worth, and J L McGuire, and M L Crane, and G P Chrousos, and R L Wilder, and I J Elenkov
Hepatitis B virus surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes/macrophages by interfering with JNK activation.
May 2013, Journal of immunology (Baltimore, Md. : 1950),
A A Link, and T Kino, and J A Worth, and J L McGuire, and M L Crane, and G P Chrousos, and R L Wilder, and I J Elenkov
Human monocytes respond to extracellular cAMP through A2A and A2B adenosine receptors.
July 2014, Journal of leukocyte biology,
A A Link, and T Kino, and J A Worth, and J L McGuire, and M L Crane, and G P Chrousos, and R L Wilder, and I J Elenkov
Human Adenosine A2A Receptor: Molecular Mechanism of Ligand Binding and Activation.
January 2017, Frontiers in pharmacology,
A A Link, and T Kino, and J A Worth, and J L McGuire, and M L Crane, and G P Chrousos, and R L Wilder, and I J Elenkov
Activation of the A2A adenosine receptor inhibits nitric oxide production in glial cells.
June 1998, FEBS letters,
A A Link, and T Kino, and J A Worth, and J L McGuire, and M L Crane, and G P Chrousos, and R L Wilder, and I J Elenkov
Prostaglandin E2 inhibits IL-23 and IL-12 production by human monocytes through down-regulation of their common p40 subunit.
March 2013, Molecular immunology,
A A Link, and T Kino, and J A Worth, and J L McGuire, and M L Crane, and G P Chrousos, and R L Wilder, and I J Elenkov
Adenosine A2 receptors on human monocytes modulate C2 production.
August 1984, Clinical and experimental immunology,
Copied contents to your clipboard!